Nilesh Shah appointed as Regional Head for AMEA at Illumina
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy JNJ?
Source: Yahoo Finance
Appointment Announcement: Illumina Inc. has appointed Nilesh Shah as Head of Region, AMEA, effective immediately.
Experience Background: Nilesh brings over 25 years of experience in medical technology and life sciences, having held senior roles at companies like Johnson & Johnson and GE Healthcare.
Vision for Genomics: Nilesh expressed his commitment to advancing genomic technologies to improve health outcomes in the AMEA region and globally.
Leadership Transition: He succeeds Bas Verhoef, who will continue as Head of Region for Europe while Nilesh will be based in Singapore.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 244.440
Low
190.00
Averages
218.50
High
240.00
Current: 244.440
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson's Strong Operations Support Dividend Growth
- Dividend Growth History: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a Dividend King, which enhances investor confidence in its ability to maintain stable payouts amid economic volatility.
- Sales Growth Projection: The company is projected to reach $100 billion in sales this year, marking it as only the second biopharma company to achieve this milestone, despite challenges from government price negotiations, showcasing its strong market position and product demand.
- Diversified Product Line: Johnson & Johnson's pharmaceutical business spans several major therapeutic areas with multiple drugs generating over $1 billion in annual sales, effectively mitigating risks associated with patent expirations and ensuring long-term profitability.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates exceptional financial health, positioning itself to perform strongly amid economic uncertainties, further solidifying its status as a preferred choice for investors.
See More
Top Dividend Stocks to Buy Now
- Strong Credit Rating: Johnson & Johnson boasts an AAA credit rating, surpassing that of the U.S. government, which underscores its financial stability and attracts investors seeking safe havens, with a dividend yield exceeding 2.1% expected to remain steady amid economic uncertainties.
- Brand Loyalty: PepsiCo has built a robust brand loyalty through its diverse food and beverage portfolio, including brands like Lay's and Gatorade, allowing it to maintain a solid 3.7% dividend yield even during inflationary periods, showcasing its strong pricing power and profitability.
- Recession Resistance: Walmart is recognized as one of the most recession-resistant stocks, operating over 3,500 supercenters and more than 1,000 smaller stores, which helps it attract consumers during economic downturns, while also increasing its dividend for 53 consecutive years, despite a modest 0.8% yield.
- Investment Recommendations: Given the heightened market uncertainties, the analyst team's recommendations for dividend stocks like Johnson & Johnson, PepsiCo, and Walmart highlight their stability and growth potential during economic downturns, making them suitable for investors seeking safe investments.
See More
Three Dividend Stocks Worth Buying Now
- Strong Credit Rating: Johnson & Johnson boasts an AAA credit rating, surpassing that of the U.S. government, with a market cap of $589 billion, indicating its robustness in uncertain markets, making it suitable for safety-seeking investors.
- Stable Dividend Growth: Johnson & Johnson has increased its dividend for 63 consecutive years, with a current yield of 2.13%, ensuring continued business growth due to the stability of healthcare demand even amidst economic fluctuations.
- Brand Loyalty: PepsiCo, with a market cap of $212 billion and a dividend yield of 3.66%, owns numerous well-known brands, and its products are considered small luxuries that consumers are likely to continue purchasing during inflation, ensuring profitability.
- Economic Resilience: Walmart is renowned for its low-price strategy and strong e-commerce presence, with a market cap of $991 billion and a dividend yield of 0.77%, attracting consumers even in economic downturns, demonstrating its risk resilience in the market.
See More
Trump Considers Exit from Iran War Amid Strait of Hormuz Closure
- War Exit Consideration: President Trump is contemplating an exit from the Iran war even if the Strait of Hormuz remains closed, a decision that could significantly impact U.S. military strategy and diplomatic relations in the Middle East.
- Positive Stock Market Reaction: The stock market surged as investors reacted positively to the potential for peace initiatives from Trump, indicating increased confidence in future geopolitical stability.
- Mixed Oil Price Movement: Despite the stock market rally, oil prices showed mixed results, reflecting concerns over energy supply security amid heightened geopolitical tensions in the Strait of Hormuz.
- Strategic Impact Assessment: Trump's potential decision could alter the U.S. role in the Middle East, affect global energy markets, and lead other nations to reassess their relationships with the United States.
See More
Trump Considers Exit from Iran War Amid Strait of Hormuz Closure
- War Exit Consideration: President Trump is contemplating an exit from the Iran war even if the Strait of Hormuz remains closed, a decision that could significantly impact U.S. military strategy and diplomatic relations in the Middle East.
- Market Reaction: Following the news, stocks surged, indicating investor optimism regarding a potential peaceful resolution, while also reflecting sensitivity to oil price fluctuations.
- Oil Price Trends: Despite the stock market rally, oil prices showed mixed movements, suggesting ongoing concerns about future supply chains and geopolitical risks that could affect the global economy.
- Geopolitical Implications: This move by Trump could alter U.S.-Iran relations, potentially affecting stability in the Middle East and the dynamics of the energy market.
See More
Johnson & Johnson: A Strong Dividend Investment Amid Market Volatility
- Dividend Growth Record: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a leader among Dividend Kings, which showcases its ability to provide stable returns during economic turmoil, thus attracting safety-seeking investors.
- Strong Sales Projections: The company is projected to achieve $100 billion in sales this year, marking it as only the second biopharma company to reach this milestone, which will enhance its market position and boost investor confidence.
- Diversified Product Portfolio: Johnson & Johnson's pharmaceutical division includes numerous drugs with annual sales exceeding $1 billion, enabling it to effectively navigate challenges posed by patent expirations, ensuring continued growth in a competitive market.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates robust financial health, allowing it to continue investing in R&D and increasing dividends amidst economic uncertainty, thereby enhancing its long-term investment appeal.
See More
Johnson & Johnson's Strong Operations Support Dividend Growth
- Dividend Growth History: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a Dividend King, which enhances investor confidence in its ability to maintain stable payouts amid economic volatility.
- Sales Growth Projection: The company is projected to reach $100 billion in sales this year, marking it as only the second biopharma company to achieve this milestone, despite challenges from government price negotiations, showcasing its strong market position and product demand.
- Diversified Product Line: Johnson & Johnson's pharmaceutical business spans several major therapeutic areas with multiple drugs generating over $1 billion in annual sales, effectively mitigating risks associated with patent expirations and ensuring long-term profitability.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates exceptional financial health, positioning itself to perform strongly amid economic uncertainties, further solidifying its status as a preferred choice for investors.
See More
Top Dividend Stocks to Buy Now
- Strong Credit Rating: Johnson & Johnson boasts an AAA credit rating, surpassing that of the U.S. government, which underscores its financial stability and attracts investors seeking safe havens, with a dividend yield exceeding 2.1% expected to remain steady amid economic uncertainties.
- Brand Loyalty: PepsiCo has built a robust brand loyalty through its diverse food and beverage portfolio, including brands like Lay's and Gatorade, allowing it to maintain a solid 3.7% dividend yield even during inflationary periods, showcasing its strong pricing power and profitability.
- Recession Resistance: Walmart is recognized as one of the most recession-resistant stocks, operating over 3,500 supercenters and more than 1,000 smaller stores, which helps it attract consumers during economic downturns, while also increasing its dividend for 53 consecutive years, despite a modest 0.8% yield.
- Investment Recommendations: Given the heightened market uncertainties, the analyst team's recommendations for dividend stocks like Johnson & Johnson, PepsiCo, and Walmart highlight their stability and growth potential during economic downturns, making them suitable for investors seeking safe investments.
See More
Three Dividend Stocks Worth Buying Now
- Strong Credit Rating: Johnson & Johnson boasts an AAA credit rating, surpassing that of the U.S. government, with a market cap of $589 billion, indicating its robustness in uncertain markets, making it suitable for safety-seeking investors.
- Stable Dividend Growth: Johnson & Johnson has increased its dividend for 63 consecutive years, with a current yield of 2.13%, ensuring continued business growth due to the stability of healthcare demand even amidst economic fluctuations.
- Brand Loyalty: PepsiCo, with a market cap of $212 billion and a dividend yield of 3.66%, owns numerous well-known brands, and its products are considered small luxuries that consumers are likely to continue purchasing during inflation, ensuring profitability.
- Economic Resilience: Walmart is renowned for its low-price strategy and strong e-commerce presence, with a market cap of $991 billion and a dividend yield of 0.77%, attracting consumers even in economic downturns, demonstrating its risk resilience in the market.
See More
Trump Considers Exit from Iran War Amid Strait of Hormuz Closure
- War Exit Consideration: President Trump is contemplating an exit from the Iran war even if the Strait of Hormuz remains closed, a decision that could significantly impact U.S. military strategy and diplomatic relations in the Middle East.
- Positive Stock Market Reaction: The stock market surged as investors reacted positively to the potential for peace initiatives from Trump, indicating increased confidence in future geopolitical stability.
- Mixed Oil Price Movement: Despite the stock market rally, oil prices showed mixed results, reflecting concerns over energy supply security amid heightened geopolitical tensions in the Strait of Hormuz.
- Strategic Impact Assessment: Trump's potential decision could alter the U.S. role in the Middle East, affect global energy markets, and lead other nations to reassess their relationships with the United States.
See More
Trump Considers Exit from Iran War Amid Strait of Hormuz Closure
- War Exit Consideration: President Trump is contemplating an exit from the Iran war even if the Strait of Hormuz remains closed, a decision that could significantly impact U.S. military strategy and diplomatic relations in the Middle East.
- Market Reaction: Following the news, stocks surged, indicating investor optimism regarding a potential peaceful resolution, while also reflecting sensitivity to oil price fluctuations.
- Oil Price Trends: Despite the stock market rally, oil prices showed mixed movements, suggesting ongoing concerns about future supply chains and geopolitical risks that could affect the global economy.
- Geopolitical Implications: This move by Trump could alter U.S.-Iran relations, potentially affecting stability in the Middle East and the dynamics of the energy market.
See More
Johnson & Johnson: A Strong Dividend Investment Amid Market Volatility
- Dividend Growth Record: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a leader among Dividend Kings, which showcases its ability to provide stable returns during economic turmoil, thus attracting safety-seeking investors.
- Strong Sales Projections: The company is projected to achieve $100 billion in sales this year, marking it as only the second biopharma company to reach this milestone, which will enhance its market position and boost investor confidence.
- Diversified Product Portfolio: Johnson & Johnson's pharmaceutical division includes numerous drugs with annual sales exceeding $1 billion, enabling it to effectively navigate challenges posed by patent expirations, ensuring continued growth in a competitive market.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates robust financial health, allowing it to continue investing in R&D and increasing dividends amidst economic uncertainty, thereby enhancing its long-term investment appeal.
See More
